Merck initiated with an Overweight at Barclays

Barclays initiated coverage of Merck (MRK) with an Overweight rating and $140 price target The firm says the company’s 2026 will bring “first-in-class” launches and pivotal data readouts. Merck shares offer potential for both earnings upside and multiple expansion, the analyst tells investors in a research note.